Vaderis Therapeutics closed an oversubscribed $152 million Series B to advance engasertib (VAD-044) for hereditary hemorrhagic telangiectasia (HHT). The financing is designed to fund the Phase 3 program as the Swiss company targets the first treatment pathway for patients with a rare bleeding disorder. The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital and existing investors including Medicxi and Droia. Vaderis’ lead program is intended to move from advanced development toward a potential regulatory filing once Phase 3 data mature. The deal underscores continued investor appetite for late-stage-orientated development in underserved rare disease indications, especially when companies can leverage translational rationale from oncology drug development approaches.